Close
Close
Treatment News

Ulcerative colitis Product granted Reimbursement in Sweden

1.0
1.0 from 3 votes
Friday, March 12, 2010

Learn more about:

Access Programs

Ulcerative colitis (UC) is a form of inflammatory bowel disease characterized by a chronic inflammation often with ulcers in the large intestine.

The symptoms of UC can differ between patients in terms of frequency and severity. The amount of the large intestine affected by UC also varies between patients. Depending of the severity of symptoms, UC may be grouped into mild, moderate and severe forms. The incidence of UC is app. 15/100,000 and there are about 30,000 patients in Sweden.

Mezavant® is indicated for induction of clinical and endoscopic remission in mild to moderate ulcerative colitis and to maintenance of remission. Mezavant is a so called 5-ASA product, i. e. it belongs to a group of inflammation inhibitors containing amino salicylic acid (ASA). Mezavant has been granted Price & Reimbursement in Sweden as per February 23, 2010.

The delivery of Mezavant differs from other 5-ASAs. Only Mezavant has Multi Matrix System Technology (MMX), designed to optimize delivery of 5-ASA to and throughout the colon. At 1200 mg per tablet, once-daily Mezavant offers the highest 5-ASA dose per tablet. Reduced pill burden and frequency of dosing may help improve compliance, a crucial factor for treatment success.

Shire Pharmaceuticals Group has launched Mezavant in USA (brand name Lialda) and in most European countries. In the Nordic countries Swedish Orphan Biovitrum has launched Mezavant in Denmark, Norway and now Sweden while Finland is expected to follow.

 

IR & Media contact:
Telephone +46 8 412 98 00
ir.media@swedishorphan.com

Source: Swedish Orphan International
1.0
1.0 from 3 votes
Free Newsletter
Related Videos
by Abidemi Uruejoma
438 views
by Abidemi Uruejoma
9,138 views